Boston Pharmaceuticals has agreed to partner with GlaxoSmithKline (GSK) again – this time for multiple pre-Phase II programmes. The first two programmes selected under the agreement are for oncology and CNS disorders: GSK3903371 and GSK3502421. Interestingly, the deal comes less than three years after Boston Pharma in-licensed five programmes from GSK, including GSK3352589 (now known as BOS-589) which has since progressed to Phase II studies for the treatment of irritable bowel syndrome.